Joakim Nyberg

Reflection on clinical and methodological issues in rare disease clinical trials.

Verbeeck, Johan; Geroldinger, Martin; Nyberg, Joakim; Thiel, Konstantin E. et al.

Ingår i Orphanet Journal of Rare Diseases, 2025

• DOI för Reflection on clinical and methodological issues in rare disease clinical trials.
• Ladda ner fulltext (pdf) av Reflection on clinical and methodological issues in rare disease clinical trials.

Optimizing designs in clinical trials with an application in treatment of Epidermolysis bullosa simplex, a rare genetic skin disease

Nyberg, Joakim; Hooker, Andrew; Zimmermann, Georg; Verbeeck, Johan et al.

Ingår i Computational Statistics & Data Analysis, 2024

• DOI för Optimizing designs in clinical trials with an application in treatment of Epidermolysis bullosa simplex, a rare genetic skin disease
• Ladda ner fulltext (pdf) av Optimizing designs in clinical trials with an application in treatment of Epidermolysis bullosa simplex, a rare genetic skin disease

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Faraj, Alan; Nyberg, Joakim; Blouse, Grant E.; Knudsen, Tom et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 498-505, 2024

• DOI för Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
• Ladda ner fulltext (pdf) av Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials

Geroldinger, Martin; Verbeeck, Johan; Hooker, Andrew C.; Thiel, Konstantin E. et al.

Ingår i Orphanet Journal of Rare Diseases, 2023

• DOI för Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials
• Ladda ner fulltext (pdf) av Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Keutzer, Lina; You, Huifang; Farnoud, Ali; Nyberg, Joakim et al.

Ingår i Pharmaceutics, 2022

• DOI för Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
• Ladda ner fulltext (pdf) av Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Reflection on clinical and methodological issues in rare disease clinical trials.

Verbeeck, Johan; Geroldinger, Martin; Nyberg, Joakim; Thiel, Konstantin E. et al.

Ingår i Orphanet Journal of Rare Diseases, 2025

• DOI för Reflection on clinical and methodological issues in rare disease clinical trials.
• Ladda ner fulltext (pdf) av Reflection on clinical and methodological issues in rare disease clinical trials.

Optimizing designs in clinical trials with an application in treatment of Epidermolysis bullosa simplex, a rare genetic skin disease

Nyberg, Joakim; Hooker, Andrew; Zimmermann, Georg; Verbeeck, Johan et al.

Ingår i Computational Statistics & Data Analysis, 2024

• DOI för Optimizing designs in clinical trials with an application in treatment of Epidermolysis bullosa simplex, a rare genetic skin disease
• Ladda ner fulltext (pdf) av Optimizing designs in clinical trials with an application in treatment of Epidermolysis bullosa simplex, a rare genetic skin disease

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Faraj, Alan; Nyberg, Joakim; Blouse, Grant E.; Knudsen, Tom et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 498-505, 2024

• DOI för Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
• Ladda ner fulltext (pdf) av Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials

Geroldinger, Martin; Verbeeck, Johan; Hooker, Andrew C.; Thiel, Konstantin E. et al.

Ingår i Orphanet Journal of Rare Diseases, 2023

• DOI för Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials
• Ladda ner fulltext (pdf) av Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Keutzer, Lina; You, Huifang; Farnoud, Ali; Nyberg, Joakim et al.

Ingår i Pharmaceutics, 2022

• DOI för Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
• Ladda ner fulltext (pdf) av Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

An introduction of the full random effects model

Yngman, Gunnar; Nyberg, Henrik B.; Nyberg, Joakim; Jonsson, E. Niclas et al.

Ingår i CPT, s. 149-160, 2022

• DOI för An introduction of the full random effects model
• Ladda ner fulltext (pdf) av An introduction of the full random effects model

Population Kinetics of 0.9% Saline Distribution in Hemorrhaged Awake and Isoflurane-anesthetized Volunteers

Nyberg, Joakim; Li, Husong; Wessmark, Pehr; Winther, Viktor et al.

Ingår i Anesthesiology, s. 501-511, 2019

• DOI för Population Kinetics of 0.9% Saline Distribution in Hemorrhaged Awake and Isoflurane-anesthetized Volunteers

PKPDSimulator.jl: A simulation engine for drug development and clinical therapeutics in Julia

Rackauckas, Christopher; Nyberg, Joakim; Ivaturi, Vijay

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2018

Implicit and efficient handling of missing covariate information using full random effects modelling

Nyberg, Joakim; Karlsson, Mats O; Jonsson, Niclas E.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2018

Second order Taylor expansion of likelihood-based models

Aoki, Yasunori; Nyberg, Joakim; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2017

Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches

Juul, Rasmus Vestergaard; Nyberg, Joakim; Kreilgaard, Mads; Christrup, Lona Louring et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 325-333, 2017

• DOI för Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches

Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

Nyberg, Joakim; Karlsson, Kristin E.; Jönsson, Siv; Yin, O. Q. P. et al.

Ingår i CPT, s. 222-232, 2016

• DOI för Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
• Ladda ner fulltext (pdf) av Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

The effect of Fisher information matrix approximation methods in population optimal design calculations

Strömberg, Eric; Nyberg, Joakim; Hooker, Andrew

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 609-619, 2016

• DOI för The effect of Fisher information matrix approximation methods in population optimal design calculations
• Ladda ner fulltext (pdf) av The effect of Fisher information matrix approximation methods in population optimal design calculations

A Pharmacokinetic-Pharmacodynamic Model of Morphine Exposure and Subsequent Morphine Consumption in Postoperative Pain

Juul, Rasmus Vestergaard; Nyberg, Joakim; Lund, Trine Meldgaard; Rasmussen, Sten et al.

Ingår i Pharmaceutical research, s. 1093-1103, 2016

• DOI för A Pharmacokinetic-Pharmacodynamic Model of Morphine Exposure and Subsequent Morphine Consumption in Postoperative Pain

Handling Underlying Discrete Variables with Mixed Hidden Markov Models in NONMEM

Plan, Elodie L.; Nyberg, Joakim; Bauer, Robert J.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2015

Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-the Hokusai-VTE phase 3 study

Niebecker, Ronald; Jönsson, Siv; Karlsson, Mats O; Miller, Raymond et al.

Ingår i British Journal of Clinical Pharmacology, s. 1374-1387, 2015

• DOI för Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-the Hokusai-VTE phase 3 study

Inter occasion variability in individual optimal design

Kristoffersson, Anders N.; Friberg, Lena E.; Nyberg, Joakim

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 735-750, 2015

• DOI för Inter occasion variability in individual optimal design
• Ladda ner fulltext (pdf) av Inter occasion variability in individual optimal design

Methods and software tools for design evaluation for population pharmacokinetics-pharmacodynamics studies

Nyberg, Joakim; Bazzoli, Caroline; Ogungbenro, Kay; Aliev, Alexander et al.

Ingår i British Journal of Clinical Pharmacology, s. 6-17, 2015

• DOI för Methods and software tools for design evaluation for population pharmacokinetics-pharmacodynamics studies

Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Ernest II, Charles; Nyberg, Joakim; Karlsson, Mats O.; Hooker, Andrew C.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 639-654, 2014

• DOI för Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
• Ladda ner fulltext (pdf) av Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Optimizing disease progression study designs for drug effect discrimination

Ueckert, Sebastian; Hennig, Stefanie; Nyberg, Joakim; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 587-596, 2013

• DOI för Optimizing disease progression study designs for drug effect discrimination

Handling of Inter Occasion Variability (IOV) in Individual Optimal Design (OD) of a Colistin PK Sampling Schedule

Kristoffersson, Anders N.; Friberg, Lena E.; Nyberg, Joakim

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2013

Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models

Vong, Camille; Bergstrand, Martin; Nyberg, Joakim; Karlsson, Mats O.

Ingår i AAPS Journal, s. 176-186, 2012

• DOI för Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models

PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

Nyberg, Joakim; Ueckert, Sebastian; Strömberg, Eric; Hennig, Stefanie et al.

Ingår i Computer Methods and Programs in Biomedicine, s. 789-805, 2012

• DOI för PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

Serial correlation in optimal design for nonlinear mixed effects models

Nyberg, Joakim; Höglund, Richard; Bergstrand, Martin; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 239-249, 2012

• DOI för Serial correlation in optimal design for nonlinear mixed effects models

Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin

Hennig, Stefanie; Nyberg, Joakim; Fanta, Samuel; Backman, Janne T. et al.

Ingår i Journal of clinical pharmacology, s. 347-360, 2012

• DOI för Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin

Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index

Lledó-García, Rocío; Hennig, Stefanie; Nyberg, Joakim; Hooker, Andrew C et al.

Ingår i Journal of clinical pharmacology, s. 29-38, 2012

• DOI för Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index

Optimised protocol design for the screening of analgesic compounds in neuropathic pain.

Taneja, A; Nyberg, J; Danhof, M; Della Pasqua, O

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 661-671, 2012

• DOI för Optimised protocol design for the screening of analgesic compounds in neuropathic pain.

Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain.

Taneja, A; Nyberg, J; de Lange, E C M; Danhof, M et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 673-681, 2012

• DOI för Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain.

Optimal Design in Population Kinetic Experiments by Set-Valued Methods

Gennemark, Peter; Danis, Alexander; Nyberg, Joakim; Hooker, Andrew C. et al.

Ingår i AAPS Journal, s. 495-507, 2011

• DOI för Optimal Design in Population Kinetic Experiments by Set-Valued Methods

Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment

Sjögren, Erik; Nyberg, Joakim; Magnusson, Mats O.; Lennernäs, Hans et al.

Ingår i Drug Metabolism And Disposition, s. 858-863, 2011

• DOI för Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment

Population Pharmacokinetic Modeling and Optimal Sampling Strategy for Bayesian Estimation of Amikacin Exposure in Critically Ill Septic Patients

Delattre, Isabelle K.; Musuamba, Flora T.; Nyberg, Joakim; Taccone, Fabio S. et al.

Ingår i Therapeutic Drug Monitoring, s. 749-756, 2010

• DOI för Population Pharmacokinetic Modeling and Optimal Sampling Strategy for Bayesian Estimation of Amikacin Exposure in Critically Ill Septic Patients

Adaptive-Optimal Design in PET Occupancy Studies

Zamuner, S.; Di Iorio, V. L.; Nyberg, Joakim; Gunn, R. N. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 563-571, 2010

• DOI för Adaptive-Optimal Design in PET Occupancy Studies

Trial treatment length optimization with an emphasis on disease progression studies

Hennig, Stefanie; Nyberg, Joakim; Hooker, Andrew C; Karlsson, Mats O

Ingår i Journal of clinical pharmacology, s. 323-335, 2009

• DOI för Trial treatment length optimization with an emphasis on disease progression studies

Simultaneous optimal experimental design on dose and sample times

Nyberg, Joakim; Karlsson, Mats O.; Hooker, Andrew C.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 125-145, 2009

• DOI för Simultaneous optimal experimental design on dose and sample times

Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design

Silber, Hanna E.; Nyberg, Joakim; Hooker, Andrew C.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 281-295, 2009

• DOI för Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design
• Ladda ner fulltext (pdf) av Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design

The Lasso – A Novel Method for Predictive Covariate Model Building in Nonlinear Mixed Effects Models

Ribbing, Jakob; Nyberg, Joakim; Caster, Ola; Jonsson, E. Niclas

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 485-517, 2007

• DOI för The Lasso – A Novel Method for Predictive Covariate Model Building in Nonlinear Mixed Effects Models

Practical Optimal Experimental Design in Drug Development and Drug Treatment using Nonlinear Mixed Effects Models

Nyberg, Joakim

2011

• Ladda ner fulltext (pdf) av Practical Optimal Experimental Design in Drug Development and Drug Treatment using Nonlinear Mixed Effects Models

Handling Below Limit of Quantification Data in Optimal Trial Design

Vong, Camille; Ueckert, Sebastian; Nyberg, Joakim; Hooker, Andrew C.

2014

Nutritional supplementation in patients after coronary-bypass surgery for unstable angina pectoris

Rapp-Kesek, Doris; Rosborg, Helena; Wilbrand, Kerstin; Nyberg, Joakim et al.

2012

Optimal Design Applied to Hematological Toxicity-Induced Anticancer Treatment

Vong, Camille; Nyberg, Joakim; Karlsson, Mats O.; Friberg, Lena E. et al.

Model-based approaches to prospectively power pediatric pharmacokinetic trials with limited sample size

Faraj, Alan; Ayoun Alsoud, Rami; Nyberg, Joakim; Simonsson, Ulrika S. H.